NYQ · Drug Manufacturers - Specialty & Generic

EBS (EBS) Stock

$6.22 +1.97% NYQ: EBS Healthcare

Valuation

MetricValue
Price$6.22
Market Cap$320.93M
P/E Ratio8.67
P/B Ratio0.80
P/S Ratio0.63
EPS (TTM)$0.93
52-Week High$14.06
52-Week Low$4.57
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE10.13%
ROA4.02%
ROCE21.03%
Gross Margin14.80%
Operating Margin14.80%
Net Margin-1.27%
Debt/Equity1.10
Current Ratio5.02

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.8B$1.1B$1.0B$1.0B$743.0M
Operating Profit$341.0M$-170.0M$-726.0M$-109.0M$110.0M
Net Profit$220.0M$-212.0M$-760.0M$-191.0M$53.0M
EPS$4.06$-4.22$-14.85$-3.60$0.93
Op Margin19.3%-15.2%-69.2%-10.4%14.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$3.0B$3.2B$1.8B$1.4B$1.3B
Total Liabilities$1.3B$1.8B$1.2B$907.0M$796.0M
Cash$576.0M$643.0M$112.0M$100.0M$205.0M
Borrowings$871.0M$1.4B$860.0M$676.0M$572.0M

Latest News

Emergent Gets $52.7 Million Contract Modification From US Government MT Newswires · Jun 29, 2026 Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government GlobeNewswire · Jun 29, 2026 Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose GlobeNewswire · Jun 4, 2026 Emergent BioSolutions Wins $64.5 Million US Government Contract Modification for BAT MT Newswires · May 28, 2026 Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy GlobeNewswire · May 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$321.0M$-34.0M$-206.0M$59.0M$171.0M
Investing Cash Flow$-450.0M$-497.0M$161.0M$102.0M$56.0M
Financing Cash Flow$-105.0M$-83.0M$-1.0M$-1.0M$-26.0M
Net Cash Flow$-45.0M$66.0M$-531.0M$-6.0M$104.0M
Free Cash Flow$96.0M$-150.0M$-258.0M$36.0M$157.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA3.76
FCF Yield31.81%
Quick Ratio2.08
Interest Coverage1.86
Return 1Y-2.09%
Return 3Y2.32%
Return 5Y-87.36%

Ownership

Insiders Held3.85%
Institutions Held86.92%
Institutions Float Held90.40%
Institutional HolderSharesReport Date
Blackrock Inc.4,341,4622026-03-31
State Street Corporation2,849,7012026-03-31
Dimensional Fund Advisors LP2,757,1582026-03-31
American Century Companies Inc2,425,7222026-03-31
Vanguard Capital Management LLC2,257,9952026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AQST $5.24 +2.54% -8.29 $657.45M 0.00%
CMPSCOMPASS Pathways plc $13.31 -0.60% -6.19 $1.28B 0.00%
CRVS $14.27 +1.64% -23.00 $1.20B 0.00%
ESPR $3.18 +0.00% -131.40 $661.15M 0.00%
OLMA $10.56 +1.25% -3.96 $922.39M 0.00%

About EBS

EBS is led by CEO Joseph C. Papa Jr., employs 900 people, headquartered in US, publicly traded since 2006.

EBS stock trades at $6.22 with a market capitalization of $320.93M. The stock is valued at a price-to-earnings (P/E) ratio of 8.67, price-to-book of 0.80, price-to-sales of 0.63. Over the past 52 weeks the stock has ranged between $4.57 and $14.06, and currently trades 55.8% below its 52-week high.

On profitability, EBS generates a return on equity (ROE) of 10.13%, return on capital employed of 21.03%, an operating margin of 14.80%, a net profit margin of -1.27%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides